Other OTC - Delayed Quote • USD
Anthera Pharmaceuticals, Inc. (ANTH)
At close: March 14 at 10:46 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2018) | Next Qtr. (Sep 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | 0.03 | -0.58 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2018) | Next Qtr. (Sep 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | 4.78M |
| Low Estimate | -- | -- | -- | 4.78M |
| High Estimate | -- | -- | -- | 4.78M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2017 | 9/30/2017 | 12/31/2017 | 3/31/2018 |
|---|---|---|---|---|
| EPS Est. | -1.09 | -0.91 | -0.66 | -0.55 |
| EPS Actual | 0.03 | -0.58 | -0.73 | -0.57 |
| Difference | 1.12 | 0.33 | -0.07 | -0.02 |
| Surprise % | 102.80% | 36.30% | -10.60% | -3.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2018) | Next Qtr. (Sep 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.46 | -0.45 | -2.19 | -1.54 |
| 30 Days Ago | -0.46 | -0.45 | -2.19 | -1.54 |
| 60 Days Ago | -0.46 | -0.45 | -2.19 | -1.54 |
| 90 Days Ago | -0.46 | -0.45 | -2.19 | -1.54 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2018) | Next Qtr. (Sep 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ANTH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.20% |
| Next Qtr. | -- | -- | -- | 9.40% |
| Current Year | -- | -- | -- | 4.40% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | 10.00% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Roth Capital: Buy | 2/21/2018 |
| Downgrade | Jefferies: Buy to Hold | 12/29/2016 |
| Downgrade | Citigroup: Buy to Neutral | 12/29/2016 |
| Initiated | Citigroup: Buy | 9/17/2015 |
| Upgrade | Citigroup: Sell to Neutral | 5/12/2015 |
| Maintains | Jefferies: Buy | 3/17/2015 |
Related Tickers
CARM Carisma Therapeutics, Inc.
1.8700
+14.72%
ATNM Actinium Pharmaceuticals, Inc.
7.17
+4.67%
ADIL Adial Pharmaceuticals, Inc.
1.9000
-1.55%
CADL Candel Therapeutics, Inc.
5.54
+7.16%
MNMD Mind Medicine (MindMed) Inc.
8.68
0.00%
PALI Palisade Bio, Inc.
4.9300
+4.67%
LGVN Longeveron Inc.
1.8700
-2.60%
JAGX Jaguar Health, Inc.
0.1799
+14.66%
NVAX Novavax, Inc.
4.0700
+2.52%